181 related articles for article (PubMed ID: 19424940)
1. Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001).
Druce MR; Kaltsas GA; Fraenkel M; Gross DJ; Grossman AB
Horm Metab Res; 2009 Sep; 41(9):697-702. PubMed ID: 19424940
[TBL] [Abstract][Full Text] [Related]
2. The diagnosis and management of malignant phaeochromocytoma and paraganglioma.
Chrisoulidou A; Kaltsas G; Ilias I; Grossman AB
Endocr Relat Cancer; 2007 Sep; 14(3):569-85. PubMed ID: 17914089
[TBL] [Abstract][Full Text] [Related]
3. [Everolimus (RAD001) and solid tumours: a 2008 summary].
Lévy A; Sauvin LA; Massard C; Soria JC
Bull Cancer; 2008 Dec; 95(12):1205-11. PubMed ID: 19091655
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer.
Manegold PC; Paringer C; Kulka U; Krimmel K; Eichhorn ME; Wilkowski R; Jauch KW; Guba M; Bruns CJ
Clin Cancer Res; 2008 Feb; 14(3):892-900. PubMed ID: 18245553
[TBL] [Abstract][Full Text] [Related]
5. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of mammalian target of rapamycin inhibition in sarcoma: present and future.
MacKenzie AR; von Mehren M
Expert Rev Anticancer Ther; 2007 Aug; 7(8):1145-54. PubMed ID: 18028023
[TBL] [Abstract][Full Text] [Related]
7. mTOR inhibitor everolimus ameliorates progressive tubular dysfunction in chronic renal failure rats.
Nakagawa S; Masuda S; Nishihara K; Inui K
Biochem Pharmacol; 2010 Jan; 79(1):67-76. PubMed ID: 19660439
[TBL] [Abstract][Full Text] [Related]
8. Malignant pheochromocytomas and paragangliomas: molecular signaling pathways and emerging therapies.
Santarpia L; Habra MA; Jiménez C
Horm Metab Res; 2009 Sep; 41(9):680-6. PubMed ID: 19343618
[TBL] [Abstract][Full Text] [Related]
9. Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas.
Oh DY; Kim TW; Park YS; Shin SJ; Shin SH; Song EK; Lee HJ; Lee KW; Bang YJ
Cancer; 2012 Dec; 118(24):6162-70. PubMed ID: 22736481
[TBL] [Abstract][Full Text] [Related]
10. Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients.
Hickerson RP; Leake D; Pho LN; Leachman SA; Kaspar RL
J Dermatol Sci; 2009 Nov; 56(2):82-8. PubMed ID: 19699613
[TBL] [Abstract][Full Text] [Related]
11. Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma.
Oudard S; Medioni J; Aylllon J; Barrascourt E; Elaidi RT; Balcaceres J; Scotte F
Expert Rev Anticancer Ther; 2009 Jun; 9(6):705-17. PubMed ID: 19496707
[TBL] [Abstract][Full Text] [Related]
12. Cyclooxygenase-2 expression correlates with phaeochromocytoma malignancy: evidence for a Bcl-2-dependent mechanism.
Cadden IS; Atkinson AB; Johnston BT; Pogue K; Connolly R; McCance D; Ardill JE; Russell CF; McGinty A
Histopathology; 2007 Dec; 51(6):743-51. PubMed ID: 17916073
[TBL] [Abstract][Full Text] [Related]
13. Composite phaeochromocytoma with malignant peripheral nerve sheath tumour and rhabdomyosarcomatous differentiation in a patient without von Recklinghausen disease.
Gupta R; Sharma A; Arora R; Vijayaraghavan M
J Clin Pathol; 2009 Jul; 62(7):659-61. PubMed ID: 19561238
[TBL] [Abstract][Full Text] [Related]
14. The clinical spectrum of phaeochromocytoma: analysis of 115 patients.
Safwat AS; Bissada NK; Seyam RM; Al Sobhi S; Hanash KA
BJU Int; 2008 Jun; 101(12):1561-4. PubMed ID: 18261156
[TBL] [Abstract][Full Text] [Related]
15. [Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma].
Shuuin T; Karashima H
Gan To Kagaku Ryoho; 2009 Jul; 36(7):1076-9. PubMed ID: 19620795
[TBL] [Abstract][Full Text] [Related]
16. Interferon alpha and rapamycin inhibit the growth of pheochromocytoma PC12 line in vitro.
Motylewska E; Lawnicka H; Kowalewicz-Kulbat M; Sicinska P; Niedziela A; Melen-Mucha G; Stepien H
Endokrynol Pol; 2013; 64(5):368-74. PubMed ID: 24186594
[TBL] [Abstract][Full Text] [Related]
17. Role of the novel mTOR inhibitor RAD001 (everolimus) in anaplastic thyroid cancer.
Papewalis C; Wuttke M; Schinner S; Willenberg HS; Baran AM; Scherbaum WA; Schott M
Horm Metab Res; 2009 Oct; 41(10):752-6. PubMed ID: 19513966
[TBL] [Abstract][Full Text] [Related]
18. Everolimus, a promising medical therapy for coronary heart disease?
Jia L; Hui RT
Med Hypotheses; 2009 Aug; 73(2):153-5. PubMed ID: 19375241
[TBL] [Abstract][Full Text] [Related]
19. Molecular targeted therapies in adrenal, pituitary and parathyroid malignancies.
Angelousi A; Dimitriadis GK; Zografos G; Nölting S; Kaltsas G; Grossman A
Endocr Relat Cancer; 2017 Jun; 24(6):R239-R259. PubMed ID: 28400402
[TBL] [Abstract][Full Text] [Related]
20. A case of giant malignant phaeochromocytoma.
Chan FK; Choi KL; Tiu SC; Shek CC; Au Yong TK
Hong Kong Med J; 2000 Sep; 6(3):325-8. PubMed ID: 11025856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
